about
Pandemic influenza A(H1N1) virus infection in solid organ transplant recipients: impact of viral and non-viral co-infection.Therapy with m-TOR inhibitors decreases the response to the pandemic influenza A H1N1 vaccine in solid organ transplant recipients.Influenza A H1N1/2009 infection in pediatric solid organ transplant recipients.Immunogenicity of pandemic influenza A H1N1/2009 adjuvanted vaccine in pediatric solid organ transplant recipients.Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosisImpact of hepatitis C virus infection on the risk of infectious complications after kidney transplantation: data from the RESITRA/REIPI cohort.Recommendations for screening of donor and recipient prior to solid organ transplantation and to minimize transmission of donor-derived infections.A review of critical periods for opportunistic infection in the new transplantation era.Visceral leishmaniasis among liver transplant recipients: an overview.Safety of liver transplantation with Chagas disease-seropositive donors for seronegative recipients.Transjugular intrahepatic portosystemic shunt for the treatment of sinusoidal obstruction syndrome in a liver transplant recipient and review of the literature.GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients.Influenza A virus infection is associated with systemic capillary leak syndrome: case report and systematic review of the literature.Cytomegalovirus infection in solid organ transplant recipients.Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations.Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations.Case Report: Successful Lung Transplantation from a Donor Seropositive for Trypanosoma cruzi Infection (Chagas Disease) to a Seronegative Recipient.Multinational case-control study of risk factors for the development of late invasive pulmonary aspergillosis following kidney transplantation.Detection of cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance.Epidemiology and Immediate Indirect Effects of Respiratory Viruses in Lung Transplant Recipients: A 5-Year Prospective Study.Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis.Effect of delaying prophylaxis against CMV in D+/R- solid organ transplant recipients in the development of CMV-specific cellular immunity and occurrence of late CMV disease.Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.Risk factors that influence the empirical treatment of patients with acute pyelonephritis: a cohort study.Daptomycin is safe and effective for the treatment of gram-positive cocci infections in solid organ transplantation.Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort.Liver biopsy-related infection in liver transplant recipients: A current matter of concern?[Tenofovir associated hypokalaemia in a patient with normal renal function].Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation.Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides.Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis.Universal prophylaxis with fluconazole for the prevention of early invasive fungal infection in low-risk liver transplant recipients.Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study.A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients.Incisional surgical site infection in kidney transplantation.Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis.Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America.Successful liver transplantation despite donor-transmitted ESBL-producing Klebsiella pneumoniae infection: Case report and review of the literature.
P50
Q30405250-E3EEC2FF-4352-4120-B9E1-F449B47164E5Q30405856-CE7AC278-28B5-4B8B-9B15-586D85FC9AE1Q30421504-4A53BCB2-1D61-4778-AC27-CBC0DBFB804BQ30430823-804F55E0-D7D2-4736-A186-7EA52F162358Q33883785-F4F90167-AE16-4327-AE28-1E28184E71C3Q34003488-ECCE32D8-F79F-4E9B-A163-380D86200216Q34400792-7528DCB0-8348-4454-91FB-9452655447EEQ36681922-711B3DCD-F56F-4D31-9623-F11A27DA8724Q37331906-23514A85-D980-44FE-A177-3DA33F6B62FDQ37880745-4A261E30-E16E-4E44-ADE0-A0FD761F9AA4Q37886889-D0C4BF5A-045A-40E5-9F13-4F0AE9B26E7FQ37934102-9346E6B9-B8CB-465C-BCA4-3CBCE2190A9BQ38578627-ADF7AA1A-ACCC-4027-B102-ECD143A0012FQ38602983-6C92C3DD-21B4-44A0-90E3-15896A34F20EQ38623310-A82E837C-A31B-4E18-9F67-A667CFA1EC83Q38822159-80E32A81-AEC1-4E9D-9574-61B080813F82Q40117205-43DA12C3-4BAE-46DB-AA5C-11CDAB76C099Q40157393-1DBF7F43-227C-4DCC-9716-D8D299CF7585Q40271648-8ABB8006-3023-4F28-9087-BAB58BAA4515Q40544268-D3BC1996-9871-4290-BF65-87A99CC34C3DQ40855547-19122A8B-9375-483B-8F2F-521F5F390D66Q41104403-7339395D-AD01-4BF9-A740-8EFFA7EDF428Q41128262-45686737-05F6-4B1D-B21E-4B266501047FQ41991746-2D7526C1-73AE-48C6-9C2D-25AB44B1EFB0Q42215009-9326A482-A367-4475-9695-E030EAA888A0Q42216221-8069B703-4D4C-4572-8BD0-EAF7F558EEB6Q42233966-5408547F-6DF6-4170-9185-C754E5448514Q43104016-88BD7680-1AB3-4F3E-BFE0-54D53E2E3EE7Q43198622-DAEEEDEB-87B4-4F71-85E9-828C077CC8E8Q44463320-284282CF-9AB0-416C-A0A0-2EAAC943548FQ44548718-172E4B8F-F576-4768-9BF9-82FB9422A74BQ44653264-97365573-8C78-4466-A4B5-52252061757FQ44784829-40719E6D-22A6-43E8-850E-FF72103DAA1AQ45363545-97ABD7D6-F47E-4E68-BE91-83DD18D51D26Q46062495-5F46E57C-C938-482E-8B47-43D7E65EA1BFQ46749250-4B52EF7D-8A87-4CE5-925D-24416C7911EDQ46819795-A4BC7505-F3D0-4879-AFDB-A87A4BEFA26AQ46826218-17493065-8681-4AA3-B5A7-441D2A507616Q47547906-1B9F5864-EE57-4A56-9A21-27F0E3EC4857Q48152905-EF8F3984-DAB4-47A0-B9AE-8D6E3631464D
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Oscar Len
@ast
Oscar Len
@en
Oscar Len
@es
Oscar Len
@nl
Oscar Len
@sl
type
label
Oscar Len
@ast
Oscar Len
@en
Oscar Len
@es
Oscar Len
@nl
Oscar Len
@sl
prefLabel
Oscar Len
@ast
Oscar Len
@en
Oscar Len
@es
Oscar Len
@nl
Oscar Len
@sl
P1053
M-9143-2014
P106
P1153
6603391453
P21
P31
P3829
P496
0000-0002-1819-3141